Company ProfilePremium

Daewoong Co., Ltd.

Company Profile Analysis

Ticker: 003090.KS주식회사 대웅

ESOMAR 23 Corporate BadgeISO Certifications Badge
Daewoong Co., Ltd. - Company showcase

Year Founded & Workforce

1945

404 Employees

Daewoong Co., Ltd. logo

Daewoong Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Daewoong Co., Ltd. Overview

Daewoong Co. is the business holding company of one of South Korea's five largest traditional pharmaceutical groups. It controls Daewoong Pharmaceutical (52.29%), which in FY2025 posted record consolidated revenue of KRW 1,570.9 bn and operating profit of KRW 196.8 bn on the strength of three in-house products: the botulinum toxin Nabota (sold as Jeuveau in the US and Nuceiva in Europe), the P-CAB acid blocker Fexuclue, and the SGLT-2 inhibitor Envlo. It also owns 100% of Daewoong Bio, a high-margin generic and API maker with FY2025 revenue of KRW 641.3 bn, and indirectly controls HanAll Biopharma through Daewoong Pharmaceutical. Group consolidated revenue first exceeded KRW 2 tn in FY2025. The equity trades at a deep holding-company discount: at early-October 2026 prices, the market value of its Daewoong Pharmaceutical stake alone exceeded its own ex-treasury market capitalisation. The main swing factors are the Medytox trade-secret appeal, US tariffs on Korean pharmaceuticals, and how the company handles its 27.7% treasury stake under Korea's amended Commercial Act.


What the company does

SubsidiaryOwnershipBusinessFY2025 scaleSource
Daewoong Pharmaceutical Co., Ltd. (KOSPI 069620)52.29% direct (61.32% with related parties incl. Daewoong Foundation 8.62%)Prescription drugs (ETC), OTC, Nabota toxin, digital healthcare, global sales; parent of HanAll BiopharmaConsolidated revenue KRW 1,570.9 bn; OP KRW 196.8 bn[S11][S27][S28]
Daewoong Bio Co., Ltd.100%Finished generics (e.g. Gliatamin, a choline alfoscerate product), APIs (UDCA), contract manufacturingRevenue KRW 641.3 bn; OP KRW 73.9 bn[S29]
HanAll Biopharma Co., Ltd. (KOSPI)≈30% held via Daewoong PharmaceuticalSpecialty pharma plus FcRn antibody R&D (batoclimab, IMVT-1402) partnered with ImmunovantRevenue KRW 155.2 bn; operating loss KRW 0.9 bn[S30][S31]
Daewoong DevelopmentSubsidiaryReal-estate rental and supply—[S1]
IDS&TrustSubsidiaryCommunication-related devices / IT—[S1]
Daewoong Life ScienceSubsidiaryFood processing and sales—[S1]
PampaegSubsidiaryPackaging of quasi-drugs—[S1]
Daewoong Management Development InstituteSubsidiaryManagement and industrial training—[S1]
Daewoong TherapeuticsGroup R&D affiliateMicroneedle drug-delivery platform (licensed to Daewoong Pharmaceutical in Feb 2026)—[S32]
Healience; Daewoong Pharma Philippines; Daewoong Pharmaceutical (Thailand); Daewoong Pharmaceutical (Indonesia); Daewoong Pharmaceutical Hongkong (intermediate holding); Daewoong Pharmaceutical JapanSubsidiaries of Daewoong PharmaceuticalHealth services and overseas sales or holding vehicles—[S27]

Daewoong Co. describes itself in its filings as the holding company of a group whose stated aim is to lead improvements in quality of life as a global healthcare group, and says it provides investment and management services to its subsidiaries [S40][S41]. It is a "business holding company" (사업지주회사): it also runs some businesses directly. Aggregator summaries of its filings list the manufacture and sale of APIs and finished drugs, real-estate leasing, a corporate training centre, research services on lifestyle-disease prevention, and facilities management [S37][S3]. Holding-company standalone revenue was roughly KRW 74 bn in FY2025 according to a recruitment-data aggregator [S19b], which is under 4% of consolidated revenue. The economic value of the company is therefore almost entirely the value of its subsidiaries.

Principal subsidiaries and what they do:

CG Bio (시지바이오), a regenerative-medicine company often described as a "Daewoong Group affiliate," is not a subsidiary of Daewoong Co. It is owned through A-Hana, which in turn is 55.84% held by Bluenet, a family company controlled by Yoon Jae-seung [S33][S34]. Its sale matters to Daewoong Co. shareholders mainly through governance and possible owner-level use of the proceeds.

Business and revenue model

Product sales dominate: Revenue is overwhelmingly product revenue: prescription drugs, OTC products and toxin sales. Daewoong Pharmaceutical says about 60% of its prescription sales now come from its own products rather than in-licensed products [S11]. That matters because in-licensed (co-promoted) products carry much lower gross margins.

Export and partnership revenue: Nabota is sold abroad largely through distribution and supply partners, the main one being Evolus in the US. Daewoong supplies finished product and receives supply revenue plus milestones. About 84% of Nabota revenue is exports [S12][S17].

Licensing revenue: Out-licensing generates upfront payments and milestones. Examples: bersiporocin Greater China rights to CS Pharmaceuticals (2023, up to USD 336 m); DWP213388 to Vitalli Bio (2023, up to USD 477 m); Envlo Latin America to Moksha8 (2023, USD 84.36 m) [S49]. These are lumpy and not separately disclosed in group revenue.

Services and digital healthcare: Daewoong Pharmaceutical's digital-healthcare unit sells or distributes connected devices and services, including the thynC smart-ward monitoring system, the FreeStyle Libre CGM, the mobiCARE wearable ECG, the CART BP ring blood-pressure monitor and the WISKY AI retinal tool. Its revenue was KRW 36.3 bn for 9M2025, then KRW 17.0 bn in Q1 2026 and KRW 15.7 bn in Q2 2026 [S12][S13][S14].

Real estate and other: Rental and training services sit at the holding company and its smaller subsidiaries. They are immaterial to group profit.

Subscription model: None disclosed.

Value-chain position, customers and end-markets

The group is vertically integrated. It produces APIs (Daewoong Bio's UDCA), formulates finished dosage forms (Hyangnam and Osong plants), produces biologics (Nabota at Hyangnam), sells to hospitals and clinics through its own sales force (ETC), reaches pharmacies and retail (OTC, including a channel into the Daiso variety-store chain), and exports through licensees. Customers are:

  1. Korean hospitals, clinics and pharmacies, reimbursed by the National Health Insurance Service (NHIS).

  2. Aesthetic practices worldwide, reached through partners (Evolus in the US and Europe; distributors in Latin America, the Middle East and North Africa, and Southeast Asia).

  3. Licensees and pharma partners (e.g. Sun Pharma in India for Fexuclue).

  4. Consumers through OTC and health-food channels.

End-markets: Korean prescription market (gastroenterology, metabolic/diabetes, liver, CNS); global aesthetic neurotoxins; and emerging-market GI and diabetes markets.

Independent characterisation

Daewoong Co. is best understood as a levered claim on Daewoong Pharmaceutical's export toxin franchise plus a cash-generating domestic generics engine (Daewoong Bio), packaged inside a family-controlled holding structure. Since 2023 the operating story has improved clearly: Daewoong Pharmaceutical's operating margin rose from 7.5% in FY2022 to 12.5% in FY2025 as high-margin Nabota exports grew from KRW 145.3 bn to KRW 228.9 bn (derived from [S11][S28][S23]). The equity story has worsened over the same period. The share price is down about 30% year-to-date to early October 2026. The main pressures are an unresolved trade-secret case with Medytox (claim raised tenfold in August 2026), an unresolved plan for the 27.7% treasury stake, and the perception that the founding family is pursuing value creation outside the listed company (the CG Bio sale).

Strategy

Stated strategy (paraphrased from management statements)

Holding-company level (Daewoong Co.): At the March 2025 AGM, CEO Yoon Jae-chun described a cycle in which innovative new drugs change their markets and fund more R&D and new growth engines. He named new-drug development, formulation technology, strategic investment in AI and digital healthcare, and global talent as the priorities [S9]. The group's long-standing vision is to be a global healthcare group leading quality-of-life improvement [S40].

Daewoong Pharmaceutical: The headline vision is "1 product, 1 trillion" (1품 1조): building single products that reach KRW 1 tn in annual sales [S20][S94]. FY2026 priorities announced with FY2025 results [S11b]:

  1. Global expansion: Fexuclue into China, Latin America and the Middle East; Nabota into the EU big-five.

  2. Realising R&D value, with a focus on obesity and oncology.

  3. New growth engines through a "total healthcare ecosystem" linking wearables and data.

Nabota: Grow to KRW 500 bn in annual sales by 2030 and become a "total aesthetics" company (skin boosters, fillers, cosmetics, recombinant toxin) [S24][S67].

Strategic initiatives in the last 24 months

DateInitiativeDetailSource
2024–2027Nabota plant 3Dedicated toxin plant; total capacity 16 m vials a year from 2027[S24]
2024–ongoingMagok C&D CenterAbout KRW 163.7 bn R&D hub in Seoul[S57b]
2025–2026Digital healthcare scale-upthynC: about 17,000 beds and about 200 hospitals. Extensions into AI endoscopy, AI medical records, home care[S14][S13][S73]
2,025OTC channel diversificationDaiso retail entry; OTC integrated with health-functional foods[S11b]
Q1 2026ETC distribution-channel streamliningSimplified wholesaler network. Temporary Q1 revenue and OP hit[S80]
Feb 2026Obesity microneedle platformExclusive global licence from Daewoong Therapeutics for microneedle patches, incl. GLP-1 (semaglutide) patch formulations[S32][S98]
May 2026IBD pipelineINV-008 licensed in from Innovo Therapeutics (KRW 662.5 bn total; KRW 6.5 bn upfront)[S99]
2025–2026Fexuclue lifecycleNew indications (gastric-ulcer Phase 3 IND, Sep 2026), multi-country Phase 3 with Indonesia[S39][S68]
Dec 2025–Jan 2026Holding-company strategic equityTreasury-share swaps into Kwangdong (4.4%) and U2Bio (15%, in-vitro diagnostics and medical IT; described as a digital-healthcare move)[S41][S42]
2,025ESG programme"CARE for People and Planet" framework at Daewoong Pharmaceutical[S62]

Medium-term targets and guidance

TargetValueOwnerSource
Daewoong Pharmaceutical FY2026 guidance (maintained May 2026)Revenue about KRW 1.5 tn; OP about KRW 220 bn (basis per Kyobo note; likely separate)Daewoong Pharmaceutical[S80]
Nabota 2030KRW 500 bn annual salesDaewoong Pharmaceutical[S24]
Envlo30 countries by 2030Daewoong Pharmaceutical[S69]
Market capitalisationKRW 5 tn in 3 years; KRW 20 tn in 10 years (stated at appointment, Mar 2024)Park Seong-soo[S92]
Daewoong Co.No quantitative financial or shareholder-return targets found in retrieved sources——

Products & Services

Product-level revenue is disclosed only for flagship brands. Pricing is set by the NHIS for reimbursed drugs and is not separately disclosed.

Aesthetics / Biologics (Daewoong Pharmaceutical, Nabota division)

ProductDescriptionTarget customerLaunch / latestCommercial dataSource
Nabota (Korea and RoW) / Jeuveau (US) / Nuceiva (EU)Botulinum toxin type A (prabotulinumtoxinA). Daewoong calls it a high-purity toxin. Approved by the FDA, EMA and Health CanadaAesthetic clinics (glabellar lines); therapeutic indications being pursued in some marketsKorea 2014; US FDA 2019FY2024 KRW 186.4 bn (+27%), about 84% exported; FY2025 KRW 228.9 bn (+19% company basis); Q2 2026 KRW 103.4 bn (exports KRW 94.1 bn, +54.2%). Cumulative sales passed KRW 1 tn at 30 Jun 2026. Approved in 69 countries, partners in about 80. Jeuveau holds more than 14% of the US aesthetic toxin market (Evolus)[S12][S23][S24][S16][S66]
Next-generation aesthetics (pipeline)Biodegradable collagen-stimulating skin booster, bio-material filler, medical-cosmetic platform, recombinant toxinAesthetic marketIn development2030 Nabota franchise target: KRW 500 bn annual sales[S24][S67]

Prescription (ETC) — in-house new drugs

ProductDescriptionTarget customerLaunchCommercial dataSource
Fexuclue (fexuprazan)Potassium-competitive acid blocker (P-CAB) for erosive oesophagitis and GERD; Korean new drug #34. Positioned against PPIs on onset, half-life and dosing convenienceGI specialists and primary careKorea Jul 2022Product sales KRW 102.0 bn FY2024, KRW 94.5 bn FY2025, KRW 19.2 bn Q1 2026 (−29.8% YoY because of distributor destocking). Co-promoted with Chong Kun Dang. Export contracts in 30 countries and approvals in 16 (incl. China, Indonesia) as of Apr 2026. India launch with Sun Pharma Apr 2025. Gastric-ulcer Phase 3 IND approved Sep 2026[S18][S55][S68][S59][S39]
Envlo (enavogliflozin)SGLT-2 inhibitor for type 2 diabetes; Korean new drug #36; mono and combination forms (incl. metformin and DPP-4 combinations)Diabetologists and primary careKorea 2023KRW 11.6 bn FY2024; KRW 12.3 bn FY2025. Filed or entered in 19 countries (Apr 2025); target 30 countries by 2030. Export contracts with 8 Latin American countries; Middle East partnership with Arcera[S18][S69][S3]
Ursa (UDCA) familyUrsodeoxycholic acid for liver function. Listed in Korean gastric-cancer guidelines for preventing gallstones after gastrectomyHepatology, GI, OTC1961; soft capsule 1974Company-reported KRW 96.2 bn (FY2024, includes OTC Ursa); Kiwoom product series KRW 88.7 bn FY2024 and KRW 92.9 bn FY2025[S12][S18]
Other ETC portfolioCo-promoted and in-licensed brands (historically including Forxiga, Lixiana, Crestor and Gemigliptin co-promotion).Hospitals and clinicsVariousDaewoong reports outpatient prescriptions above KRW 1 tn for two consecutive years (2023–24)[S70][S71]

OTC & consumer health

ProductDescriptionNotesSource
Ursa (OTC strengths), Impactamin (vitamin B), EasyN6 (analgesic), Bearse (digestive), C-ColdLeading Korean OTC brandsOTC division revenue KRW 162.6 bn in FY2025 on the company's presentation basis. Growth helped by Daiso retail distribution[S11b][S72]
Health-functional foodsSupplements, now managed alongside OTCLinked to OTC from 2025[S11b]

Digital healthcare (Daewoong Pharmaceutical)

ProductDescriptionDataSource
thynCWearable-based smart-ward patient monitoring, developed with AI med-tech firm Seers Technology. First Korean digital-health device to obtain a remote-monitoring reimbursement code (EX871)About 17,000 beds installed (6,000 added in Q1 2026); about 200 hospitals incl. Hanyang University and Chonnam National University hospitals. Revenue is recognised with a lag of about 6 months[S12][S14][S73]
FreeStyle Libre (distributed)Continuous glucose monitor—[S12]
mobiCAREWearable ECG—[S12]
CART BPRing-type continuous blood-pressure monitor—[S12]
WISKYAI diagnostic aid for blinding retinal disease—[S12]
AI endoscopy, AI medical records, home careExpansion areas named in Q2 2026Division revenue: KRW 17.0 bn Q1 2026, KRW 15.7 bn Q2 2026 (+27% YoY)[S13]

Daewoong Bio (100% subsidiary)

ProductDescriptionDataSource
GliataminCholine alfoscerate (cognitive-function agent)Prescriptions approaching KRW 200 bn a year. Close to 30% of Daewoong Bio revenue in 2024[S29][S74]
Beacept, rabeprazole low-dose, donepezil–memantine combination, orally dissolving migraine productBranded genericsDaewoong Bio ranked 6th in the Korean outpatient prescription market in H1 2025[S75]
UDCA APIUrsodeoxycholic acid API (domestic and export)Historic core API business[S75]
Global CMOContract manufacturingDaewoong Bio described as having entered global CMO[S9]

HanAll Biopharma (≈30% via Daewoong Pharmaceutical)

Product / assetDescriptionDataSource
BiotopProbiotic drugKRW 23.8 bn sales (2025); 2026 target about KRW 30 bn[S30]
Hairgro (finasteride 1 mg) and hair-loss lineNo.1 share among finasteride 1 mg genericsHair-loss line above KRW 10 bn[S30]
EligardLeuprolide (prostate cancer, precocious puberty)—[S30]
Batoclimab (HL161BKN / IMVT-1401)Anti-FcRn antibody partnered with Immunovant/RoivantMet primary endpoint in myasthenia gravis Phase 3. Both thyroid eye disease (TED) Phase 3 trials failed their primary endpoints (2 Apr 2026). HanAll had been preparing Japan commercialisation[S30][S31][S76]
IMVT-1402 (HL161ANS, imeroprubart)Next-generation FcRn antibodyPhase 2 or registrational studies in 6 indications. Graves' disease registrational data in 2027; rheumatoid-arthritis pivotal early data and cutaneous lupus PoC in 2026[S30][S77]
TanfanerceptTNF inhibitor for dry eyeVELOS-4 Phase 3 topline in 2026[S30]
HL192Nurr1 activator for Parkinson'sNext clinical stage targeted[S30]

Financial Narrative

Income statement

Sources: Revenue and OP FY2021 [S22], FY2022 [S21], FY2023 revenue [S20], FY2024 [S9], FY2025 [S10]. FY2023 OP, gross profit and FY2021–22 controlling NI and EPS from an aggregator [S5a]. FY2023–24 NI and EPS from the KRX quarterly report summary [S40]. FY2025 controlling NI and EPS from an aggregator [S5a], cross-checked against 9M2025 controlling NI of KRW 105.2 bn [S40]. DPS [S9][S45][S2]. Margins and growth derived (FY2021 growth uses FY2020 revenue of KRW 1,355.3 bn [S22b]). The Paasa aggregator shows FY2025 OP of KRW 260.5 bn against the company's KRW 262.05 bn; the company figure is used. FY2025 gross profit is shown by aggregators only as "≈KRW 1.1 tn" (about 53% gross margin on a trailing basis [S5b]); it is left blank in the chart table because a precise figure was not available.

Revenue CAGR FY2021–FY2025: 8.2% (derived).

Commentary.

Revenue: The group has grown every year, but the rate halved after FY2022 (about 12% in FY2021–22, about 7% in FY2023–25). Growth now comes mostly from Nabota exports, Daewoong Bio's generics and Fexuclue/Envlo volume. Domestic ETC price cuts weigh on it.

Operating profit: FY2024 was the peak at KRW 281.9 bn and a 14.6% margin [S9]. The FY2025 decline to KRW 262.05 bn (−7.0%) [S10] happened despite Daewoong Pharmaceutical's 33% OP growth, and is explained by weaker Daewoong Bio and HanAll profits plus an unexplained residual.

Net income: Net income is volatile because of below-the-line items at Daewoong Pharmaceutical. In FY2024 Daewoong Pharmaceutical's net income fell to KRW 23.3 bn, in part from an impairment of previously capitalised Fexuclue clinical costs after a trial redesign (reported in 2024 [S78]) and litigation provisions. It recovered to KRW 192.9 bn in FY2025, helped by other income of KRW 59.1 bn, partly one-off [S79]. The group's FY2025 net income of KRW 222.37 bn (+222.9%) reflects that rebound [S10].

EBITDA: Not disclosed in retrieved sources. A US valuation aggregator puts last-fiscal-year EBITDA at about USD 231 m [S4]; it is not used in the chart table because of currency and definition uncertainty.

Recent quarterly trajectory

Sources: Daewoong Co. quarterly revenue from Google Finance [S2][S36]. Q1 2025 is derived from the FY2025 total. Q1 2026 revenue (+2.3% YoY) is confirmed by [S38]. Daewoong Pharmaceutical quarterly data from company releases and broker reviews [S13][S80][S81]. Q3 2025 is derived from the full-year total.

Q1 2026 was weak because Daewoong Pharmaceutical deliberately streamlined its ETC distribution channels, which cut shipments; consolidated OP fell 42.6% [S80]. Q2 2026 was a record quarter: consolidated revenue KRW 448.5 bn (+10.6%) and OP KRW 68.1 bn (+17.7%), above consensus of KRW 424.4 bn and KRW 63.1 bn [S13][S81]. Part of this was Evolus building inventory early ahead of a US tariff on Korean patented pharmaceuticals effective 29 Sep 2026 [S14]. Daewoong Co.'s Q2 2026 revenue of KRW 570.8 bn was also a record. Its Q2 2026 OP is not company-confirmed in the sources; Google Finance line items imply about KRW 76.6 bn (derived).

Balance sheet

Sources: Valueline consolidated balance sheet [S82]; KRX quarterly-report summary for FY2023–24 current liabilities [S40]. FY2025 total assets and liabilities are from Valueline's 2025/12 column; FY2025 equity is derived. Latest (31 Mar 2026): total assets KRW 3,407.7 bn, liabilities KRW 1,554.6 bn, equity KRW 1,853.1 bn, cash KRW 259.7 bn [S82]. 30 Sep 2025: total assets KRW 3,096.5 bn, current liabilities KRW 784.1 bn, equity KRW 1,628.6 bn [S40].

  • Total debt (short/long split), net debt, goodwill and intangibles, working capital: not disclosed in the sources retrieved for the holding company. Daewoong Pharmaceutical's own net debt was estimated at KRW 355 bn (FY2023) and KRW 576 bn (FY2024) by Samsung Securities. Its liabilities-to-equity ratio was about 125% at Q3 2025, after corporate bond issuance of KRW 195 bn (2024) and KRW 140 bn (2025) to fund the third Nabota plant and the Magok C&D centre [S83].

Holding company standalone (separate) balance sheet: total assets KRW 415.7 bn (FY2021), 467.0 (FY2022), 514.9 (FY2023), 543.9 (FY2024), 547.0 (Q3 2025). Liabilities KRW 50.5 bn at FY2024. The separate liabilities-to-equity ratio was 9.3% at Q3 2025 [S84][S40]. The parent itself carries almost no debt; leverage sits at Daewoong Pharmaceutical.

Balance-sheet commentary. Group assets grew by about KRW 1.07 tn between FY2022 and FY2025, while liabilities grew by about KRW 585 bn, funded largely by subsidiary bond issuance for capex. The current ratio fell from about 1.33 (FY2024, derived) to 1.01 in June 2026 per an aggregator [S85]. That is the lowest in ten years, reflecting bond maturities moving into current liabilities and capex drawdowns. It is a liquidity watch-point, not a solvency concern, given the parent's net cash and dividend inflows.

Cash flow: notes and sources

Sources: OCF from Paasa [S5a] and Stoxray [S5c] (consistent). FY2025 dividends are the declared total for FY2025 (KRW 8.29 bn), paid in 2026 [S45]. FY2023 buyback: Daewoong Co. bought KRW 10 bn of treasury shares in July 2023 [S20]. Known major capex at Daewoong Pharmaceutical: about KRW 101.4 bn for the new Nabota plant and KRW 163.7 bn for the Magok C&D centre [S57b].

Ratios

All ratios are derived–6.3. ROE and ROA use net income including minorities over average equity and assets. Aggregators show trailing ROE of 14.5%–16.3% in 2026 [S38][S36]. ROIC, net debt/EBITDA, interest coverage and cash conversion cycle for the holding company could not be computed from the data retrieved. Daewoong Pharmaceutical's interest coverage was 21.2x (FY2024) per Samsung Securities [S83].

Trend synthesis. Profitability recovered in FY2025, but mostly below the operating line. Asset turnover is falling as capital is deployed in plants that are not yet producing (the new Nabota plant starts in 2027). Payout is extremely low at about 5% of controlling profit, and this is the central capital-allocation criticism of the stock.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

Entity (KRW Bn)FY2023FY2024FY2025

Daewoong Co. consolidated revenue

1,813.81,936.92,068.6

Daewoong Pharmaceutical consolidated revenue

1,375.31,422.71,570.9

Daewoong Bio revenue

511.7579.7641.3

HanAll Biopharma revenue (inside Daewoong Pharmaceutical)

134.9138.9155.2

Operating profit by entity (KRW Bn)

Operating profit by entity (KRW Bn)FY2023FY2024FY2025

Daewoong Co. consolidated OP

195.9281.9262.1

Daewoong Pharmaceutical consolidated OP

122.6147.9196.8

Daewoong Bio OP

60.880.573.9

HanAll Biopharma OP

——-0.9

OP margin by entity (%)

OP margin by entity (%)FY2023FY2024FY2025

Daewoong Co. consolidated

10.814.612.7

Daewoong Pharmaceutical consolidated

8.910.412.5

Daewoong Bio

11.913.911.5

Revenue by Segment

Division (KRW Bn)FY2023FY2024FY2025

ETC (prescription)

872.5860.5894.2

OTC (incl. health-functional foods from 2025 presentation)

115.2133.3162.6

Nabota (botulinum toxin, domestic + export)

145.3186.4228.9

Other separate (global, digital healthcare, other; derived residual)

89.085.2105.3

Separate-company revenue

1,222.01,265.41,391.0

Consolidation and subsidiaries (derived: consolidated minus separate)

153.3157.3179.9

Consolidated revenue

1,375.31,422.71,570.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Division YoY growth (%)

Division YoY growth (%)FY2024FY2025

ETC

-1.43.9

Nabota

28.322.8

Consolidated revenue

3.410.4

Share of Daewoong Pharmaceutical consolidated revenue (%)

Share of Daewoong Pharmaceutical consolidated revenue (%)FY2023FY2024FY2025

ETC

63.460.556.9

Nabota

10.613.114.6

OTC

8.49.410.4

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

1,511.41,697.31,813.81,936.92,068.6

Revenue growth YoY (%)

11.512.36.96.86.8

Gross profit (KRW Bn)

763.2899.7931.2——

Operating profit (KRW Bn)

182.6207.3195.9281.9262.1

Net income incl. minorities (KRW Bn)

——191.468.9222.4

Net income to controlling shareholders (KRW Bn)

78.7102.6152.757.9175.1

EPS basic (KRW)

1,894.692,466.883,6921,4164,280

Dividend per share (KRW)

——100200200

Gross margin (%)

50.553.051.3——

Operating margin (%)

12.112.210.814.612.7

Net margin, controlling (%)

5.26.08.43.08.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement

MetricQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Daewoong Co. revenue (KRW Bn)

481.7528.4542.2516.3492.7570.8

Daewoong Pharmaceutical consolidated revenue (KRW Bn)

351.6405.4416.8397.1377.8448.5

Daewoong Pharmaceutical consolidated OP (KRW Bn)

38.357.957.243.422.268.1

Balance Sheet and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025

Total assets (KRW Bn)

2,158.92,359.32,720.73,232.2

Current assets (KRW Bn)

954.0862.5953.71,032.4

Cash and cash equivalents (KRW Bn)

190.4161.7191.5255.9

Short-term financial assets (KRW Bn)

130.379.862.526.4

Current liabilities (KRW Bn)

—691.0716.2—

Total liabilities (KRW Bn)

879.4922.51,218.21,464.8

Total equity incl. minorities (KRW Bn)

1,279.51,436.81,502.51,767.4

Liabilities / equity (%)

68.764.281.182.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Dividends & Capital Returns

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (KRW Bn)

133.2149.1205.7162.4257.6

Dividends paid by Daewoong Co. (KRW Bn, approx.)

————8.3

Share buybacks (KRW Bn)

——10.0——

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025

ROE on average total equity (%)

—14.14.713.6

ROA on average total assets (%)

—8.52.77.5

Asset turnover (x)

—0.800.760.69

Current ratio (x)

—1.251.33—

Liabilities / equity (x)

0.690.640.810.83

Dividend payout on controlling NI (%)

———4.7

Revenue by Region and Revenue by Region (%)

MetricFY2024FY2025H1 2026

Nabota total revenue (KRW Bn)

186.4228.9155.3

Nabota export revenue (KRW Bn, approx.)

156.6——

Nabota domestic revenue (KRW Bn, approx.)

29.8——

Export share of Nabota (%)

84——

Revenue by Region and Revenue by Region (%) (FY2024–FY2026 guidance (mid))

MetricFY2024FY2025FY2026 guidance (mid)

Evolus total net revenue (USD Mn)

265.4297.2332.0

Evolus international share of revenue (%)

58—

Share Price

MetricFY2022FY2023FY2024FY2025

Year-end share price (KRW)

20,35020,65021,60022,050

Share Price & Returns

PeriodReturn (%)

Year-to-date 2026 (vs 31 Dec 2025)

-30.4

1 year (vs 30 Sep 2025 close of KRW 21,950)

-30.1

Since end-2022 (≈3.75 years)

-24.6

5 years (per Paasa, late Sep/Oct 2026)

-50.9

Valuation Multiples

MultipleGross shares (58.14 m)Ex-treasury (≈42.04 m)Note

Market cap (KRW Bn)

891.9644.9

derived

P/E on FY2025 controlling NI (x)

5.13.7

derived; aggregators show TTM 3.6–5.4 [S37][S38]

P/B (x)

0.780.56

aggregators [S38][S39]

EV/EBITDA, EV/Sales

Not computed (net debt not available)

——

Dividend yield (%)

1.31.3

derived

Per-Share Data and Dividends & Capital Returns

MetricFY2023FY2024FY2025

DPS (KRW)

100200200

Total dividend (KRW Bn)

——8.29

Valuation Snapshot

MetricValue

Treasury ratio, end-2010

28.14%

Treasury ratio, end-2020

28.54%

Treasury ratio, end-2024

29.67%

Treasury ratio after Kwangdong swap

28.67%

Treasury ratio, 31 Aug 2026

27.70% (16,105,105 shares)

Jul 2023 buyback

KRW 10 bn

Buyback authorisation outstanding

None found

Statutory deadline to cancel pre-existing treasury shares or obtain shareholder approval for a holding plan

5 Sep 2027

Analyst Conclusions

Guidance and expectations

  • Daewoong Pharmaceutical FY2026 guidance (maintained May 2026): revenue about KRW 1.5 tn and OP about KRW 220 bn [S80].

Broker forecasts for Daewoong Pharmaceutical: consolidated FY2026 revenue KRW 1.71–1.73 tn and OP KRW 209–247 bn (DS/Kiwoom ranges; Kiwoom FY2026F OP KRW 247.0 bn as of Feb 2026, with later notes lower) [S81][S133].

H1 2026 actual: consolidated revenue KRW 826.3 bn (+10.6%) and OP KRW 90.3 bn (+17.7%) [S134].

Daewoong Co.: no guidance and no consensus.

Evolus: FY2026 revenue USD 327–337 m; 2028 target USD 450–500 m [S86].

Bull case

  1. Sum-of-parts asymmetry. At current prices the listed stake in Daewoong Pharmaceutical (≈KRW 656 bn) more than covers Daewoong Co.'s ex-treasury market cap (≈KRW 645 bn). Investors get Daewoong Bio (FY2025 OP KRW 73.9 bn), the real estate and the subsidiaries for free (derived). Mandatory treasury-share action by September 2027 is a forcing event for value realisation.

  2. Nabota operating leverage. Exports grew 54% in Q2 2026. With capacity tripling in 2027, a credible path to the KRW 500 bn 2030 target would roughly double the franchise from FY2025's KRW 228.9 bn at gross margins far above group average [S16][S24].

  3. Litigation optionality. A favourable or limited appellate outcome in January 2027 would remove the largest overhang; the cumulative provision is only KRW 57.96 bn [S56b].

Bear case

  1. Adverse Medytox ruling. Confirmation of the manufacturing and sales injunction would threaten Daewoong Pharmaceutical's largest product (about 21% of separate revenue) and could bring damages far above provisions (claim KRW 500.1 bn) [S57][S117].

  2. Tariff and partner risk. The 15% US tariff from late September 2026 and the pull-forward in Q2 2026 point to softer H2 2026 and Q1 2027 export prints. Evolus's own margins are thin [S86][S14].

  3. Governance discount persists. The holding company's FY2025 OP fell 7% even as the main subsidiary's grew 33%. Payout is about 5%, and treasury shares have been used for swaps with friendly parties rather than cancelled. The discount may be structural rather than cyclical [S10][S41][S42].

Catalysts and monitorables (next 12 months)

TimingCatalyst
Late Oct–Nov 2026Q3 2026 results (Daewoong Pharmaceutical, then Daewoong Co.): Nabota payback after pull-forward; ETC normalisation
End-2026cGMP certification of the new Nabota plant
Q4 2026CG Bio SPA (TA Associates) and any announced use of proceeds touching Daewoong Co. shares
January 2027Seoul High Court judgment in Medytox v. Daewoong
H1 2027Bersiporocin Phase 2 topline
March 2027 AGMTreasury-share holding or cancellation plan (deadline Sep 2027); dividend decision
2026–2027HanAll/Immunovant readouts: IMVT-1402 RA and CLE data in 2026; Graves' in 2027
OngoingUS tariff exemptions or adjustments; Evolus guidance updates

Analyst verdict

Daewoong Co. is a holding company whose operating fundamentals and equity performance have moved in opposite directions. Operationally, the group has never been larger. Consolidated revenue passed KRW 2 tn in FY2025. Daewoong Pharmaceutical's operating margin reached 12.5%, and Q2 2026 set records on the back of a toxin franchise that has compounded at 57% a year since FY2019 [S10][S11][S24]. Nabota capacity triples in 2027, the pipeline has a credible first-in-class read-out in H1 2027, and Daewoong Bio remains a reliable cash generator.

The equity case does not rest on operations, however. It rests on three non-operating questions. The first is litigation: a January 2027 appellate ruling will decide whether the Nabota franchise operates free of a stayed injunction, and whether damages sit near the KRW 57.96 bn provision or closer to the KRW 500.1 bn claim. The second is trade: a 15% US tariff and a pull-forward of shipments make H2 2026 export comparisons unflattering. The third, and decisive for this security specifically, is governance. With 27.7% of shares in treasury, a payout of about 5%, a KCGS B rating and an owner-level asset sale running alongside the listed company, investors are entitled to doubt that value will reach minority holders.

The valuation already discounts a great deal. The stock trades below the market value of its Daewoong Pharmaceutical stake alone, at about 0.56x book on an ex-treasury basis and below 4x earnings. That points to a favourable risk-reward for patient investors, but only if the treasury-share decision required by September 2027 results in cancellation rather than further swaps with friendly parties.

Our view: fundamentally undervalued but catalyst-dependent. We would treat Daewoong Co. as an event-driven position sized for a binary January 2027 litigation outcome. The 2027 AGM's treasury-share resolution is the most important piece of evidence on whether the holding-company discount can narrow.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleSince / tenure notesBackground

Yoon Jae-chun

CEO (representative director) and Vice Chairman

Long-serving CEO (in role by 2017). Re-elected 2022 and March 2025

Long-time Daewoong executive; previously also co-CEO of Daewoong Pharmaceutical (to 2023)

Song Ki-ho

Inside director (Vice President)

Elected Mar 2023

Daewoong Co. executive

Park Seong-soo

Other non-executive director

Elected Mar 2025

Co-CEO of Daewoong Pharmaceutical (see below)

Lee Hoon-seok

Outside director

—

Corporate-law adviser, Bae, Kim & Lee (Taepyeong)

Kang Young-chul

Outside director

—

Visiting professor, KDI School of Public Policy

Choi In-hyuk

Outside director

Elected Mar 2023.

Former NAVER executive

Yoo Seung-shin

Outside director

Elected Mar 2025

Former CEO, Helixmith

Woo Jong-soo

Outside director

Elected Mar 2025

CEO, W Science; former Hanmi Pharmaceutical CEO

Jeon Woo-bang

Standing statutory auditor

Re-elected Mar 2023

Former head of planning and coordination at Daewoong Co.; ex-VP Daewoong Bio

Yoon Jae-seung

Chief Vision Officer (CVO), group

Largest individual shareholder (11.64%)

Third son of the founder. Former chairman. A board seat at Daewoong Co. is not shown in retrieved sources

Executive Leadership Team

NameRoleSinceBackground

Lee Chang-jae

Co-CEO (marketing and domestic sales)

Co-CEO from 2022 per press; inside director since 2021; re-elected 2024

Long-time Daewoong marketing executive

Park Seong-soo

Co-CEO (R&D and overseas business)

Co-CEO since Mar 2024; inside director re-election proposed Mar 2026

Joined 1999; master's degree from Seoul National University College of Pharmacy. Former head of the US subsidiary and of the Nabota division (from 2015). At his appointment he set market-cap targets of KRW 5 tn in 3 years and KRW 20 tn in 10 years

Park Eun-kyung

Inside director; head of CH marketing

Since Mar 2024

Former ETC marketing head

Yoon Jun-soo

Head, Nabota business division

——

Cho Young-min

Outside director

Mar 2024

Professor of internal medicine, Seoul National University College of Medicine

Kwon Soon-yong

Outside director

Mar 2025

Professor, Seoul St. Mary's Hospital

Choi In-hyuk, Choi Dae-hyun

Outside directors (proposed Mar 2026)

Mar 2026

Former NAVER executive; CEO of KDB Capital/Investment affiliate

Lee Kun-haeng

Standing auditor

Retired 26 Mar 2026

Not a finance specialist (criticised in the press)

Major Shareholders

HolderStake (%)Date

Treasury shares

27.70

31 Aug 2026

Yoon Jae-seung (CVO)

11.64

2025–26

Daewoong Foundation

9.982026

Yoon Jae-yong (founder's eldest son)

7.012025

National Pension Service

3.98

1 Oct 2025 (down from 5.01% in Apr 2025)

Hananuri (ex-M Circle; Yoon Jae-seung-linked)

1.772026

Kwangdong Pharmaceutical (from treasury-share swap)

about 1.0

Dec 2025

U2Bio (from treasury-share swap)

0.97

Jan 2026

Bluenet

0.262026

Yoon Su-min, Yoon Su-jin (twins)

0.02 each

2026

Major shareholder group total (as filed)

38.04

31 Aug 2026

Competitive Landscape

Competitors by Segment

SegmentCompetitorPositioning vs DaewoongFY2025 data (KRW Bn)

Korean traditional pharma

Yuhan Corp.

No.1 by revenue; Leclaza lung-cancer royalties

Revenue 2186.6; OP 104.4

Korean traditional pharma

GC Biopharma

Plasma products (Alyglo in the US)

Revenue 1991.3; OP 69.1

Korean traditional pharma

Chong Kun Dang

Generics and in-licensing; Fexuclue co-promoter

Revenue 1692.4; OP 80.5

Korean traditional pharma

Kwangdong Pharmaceutical

Consumer and beverage-heavy; now a mutual shareholder

Revenue 1659.5; OP 31.0

Korean traditional pharma

Hanmi Pharmaceutical

Highest margins; Rosuzet; GLP-2 licensing to Lilly

Revenue 1547.5; OP 257.8

Korean traditional pharma

HK inno.N

K-CAB (tegoprazan), the main P-CAB rival to Fexuclue

Revenue above 1000; OP 110.9

Korean traditional pharma

Boryung

Oncology and cardiovascular

OP 65.1

Holding-company peer

Hanmi Science

Hanmi group holding company

Revenue 1356.8

Botulinum toxin (Korea)

Hugel

Botulax/Letybo; 47% margin; US launch with a hybrid direct model

Revenue 425.1; OP 201.6

Botulinum toxin (Korea)

Medytox

Litigant against Daewoong; weak profitability

OP 17.0 (6.9% margin; revenue about 246, derived)

Botulinum toxin (global)

AbbVie (Botox), Ipsen/Galderma (Dysport), Merz (Xeomin), Revance (Daxxify)

Global leaders

—

SGLT-2

AstraZeneca (Forxiga), Boehringer/Lilly (Jardiance) and generics

Envlo is a local challenger

—

Choline alfoscerate and generics

Chong Kun Dang and others

Daewoong Bio is a top-6 outpatient prescriber

—

Peer Comparison FY2026

MetricDaewoong Co.Daewoong PharmaceuticalYuhanGC BiopharmaHanmi Pharmaceutical

Revenue (KRW Bn)

2,068.61,570.92,186.61,991.31,547.5

Revenue growth (%)

6.810.45.818.53.5

Operating margin (%)

12.712.54.83.516.7

Expensed R&D / revenue (%)

—11.5———

Company Snapshot

$1,455.7M

Revenue

404

Employees

1945

Founded

Seongnam, South Korea

Headquarters

SWOT Analysis

Strengths

  • Export-led margin engine. Nabota grew from KRW 145.3 bn (FY2023) to KRW 228.9 bn (FY2025), with about 84% exported. It is Daewoong Pharmaceutical's largest single product (about 21% of separate revenue in H1 2026) [S65][S11b][S57].
  • Regulatory credentials. Approved by the FDA, EMA and Health Canada; approvals in 69 countries [S24].
  • In-house innovation track record. Three self-developed or self-commercialised new drugs since 2019. Fexuclue reached KRW 102.0 bn in FY2024 [S18][S54].
  • Diversified cash flows. Daewoong Bio's revenue grew from KRW 468.4 bn (2022) to KRW 641.3 bn (2025) with margins above 10% for 10 straight years [S100][S29].
  • Low parent-level leverage. Separate liabilities-to-equity of 9.3% at Q3 2025 [S84].
  • Improved subsidiary ESG standing. Daewoong Pharmaceutical rose from KCGS C (2021) to A (2025) [S62b].

Weaknesses

  • Holding-company governance lags. Daewoong Co. is rated KCGS B overall versus A at Daewoong Pharmaceutical [S61].
  • Minimal shareholder return. DPS of KRW 200 equals a payout of about 4.7% and a yield of about 1.3% [S45]; minority stock-dividend proposals were rejected in 2022, 2023 and 2025 [S9][S21][S22].
  • Holding-level profit decline in FY2025. Group OP fell 7.0% despite +33% at Daewoong Pharmaceutical, and the cause is not explained publicly [S10].
  • Volatile below-the-line earnings. Daewoong Pharmaceutical's NI was KRW 23.3 bn in FY2024, then KRW 192.9 bn in FY2025 [S11][S79].
  • Fexuclue softness. FY2025 product sales of KRW 94.5 bn fell from KRW 102.0 bn; Q1 2026 was down 29.8% [S18].
  • Tightening liquidity. The consolidated current ratio fell to 1.01 in June 2026, a 10-year low [S85].

Opportunities

  • Capacity tripling. Nabota capacity rises from 5 m to 16 m vials in 2027, against a KRW 500 bn 2030 target [S24].
  • Bersiporocin. Phase 2 topline in H1 2027 for an FDA Fast Track, first-in-class IPF asset [S111].
  • Treasury-share cancellation. Mandatory under the amended Commercial Act by 5 Sep 2027. Cancelling 27.7% of shares would mechanically lift EPS and book value per share by about 38% [S64]; derived.
  • Holdco discount. The Daewoong Pharmaceutical stake alone (6,058,200 shares × KRW 108,300 ≈ KRW 656 bn) exceeds Daewoong Co.'s ex-treasury market cap (≈KRW 645 bn), with Daewoong Bio and real estate implied at zero (derived; prices 22 Sep and 2 Oct 2026) [S27][S125][S37].
  • Emerging-market rollout. Fexuclue in 30 contracted countries; Envlo targeted for 30 countries by 2030 [S68][S69].
  • Digital healthcare. thynC growth (about 17,000 beds) with a 6-month revenue-recognition lag that pushes inflection into 2027 [S14][S80].

Threats

  • Medytox appeal. Claim of KRW 500.1 bn. The first instance ordered a production and sales ban (stayed) and KRW 40 bn damages. Judgment is expected in January 2027 [S57][S117].
  • US tariff. 15% on Korean patented pharmaceuticals from 29 Sep 2026 [S86].
  • HanAll setback. Batoclimab TED Phase 3 failure (Apr 2026) weakens HanAll's valuation inside Daewoong Pharmaceutical [S31].
  • Toxin competition. Hugel's US push with a hybrid direct model (Americas revenue +105% in 2025) [S122].
  • Korean pricing reform. Ongoing drug-price cuts and re-evaluations hit ETC [S18].
  • Governance overhang. Owner-level transactions (CG Bio) and the treasury-share decision could dilute or disadvantage minorities [S34][S109].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
7 Apr 2025Fexuclue launched in India with Sun Pharma [S59]First large emerging-market P-CAB launch
28 Apr 2025Q1 2025: Daewoong Pharmaceutical consolidated revenue KRW 351.6 bn, OP KRW 38.3 bn (+54.4%) [S114]Margin recovery begins
Q2 2025Korean price cut hits Fexuclue [S18]Domestic pricing pressure on a flagship product
31 Jul 2025Q2 2025: consolidated revenue KRW 405.4 bn; separate OP KRW 62.5 bn; record Nabota shipments [S115]Beat on Nabota and OTC
27 Sep 2025Third IDMC recommends continuing the bersiporocin Phase 2 [S112]Safety de-risking
1 Oct 2025NPS cuts its Daewoong Co. stake to 3.98% from 5.01% [S6b]Reduced institutional anchor
7 Nov 2025Q3 2025: separate revenue KRW 355.1 bn, OP KRW 53.5 bn; Nabota KRW 55.3 bn (84.8% export); digital healthcare 9M KRW 36.3 bn [S17]Broad growth
Nov 2025KCGS 2025: Daewoong Pharmaceutical A; Daewoong Co. B (Social A+) [S61][S62]Governance gap between holding company and subsidiary
24 Dec 2025Treasury-share swap with Kwangdong Pharmaceutical [S41]Pre-emptive treasury-share move ahead of the Commercial Act amendment
29 Dec 2025Ex-dividend date for KRW 200 DPS [S3]Payout unchanged
12 Jan 2026Treasury-share swap for a 15% U2Bio stake [S42]Same; digital-healthcare rationale
9 Feb 2026FY2025 preliminary results: group revenue KRW 2,068.6 bn, OP KRW 262.05 bn (−7.0%), NI KRW 222.37 bn; Daewoong Pharmaceutical record year [S10]First KRW 2 tn group year; holding-company margin down
25 Feb 2026FY2025 DPS of KRW 200 declared (KRW 8.29 bn) [S45]Payout about 5%
25 Feb 2026National Assembly passes the third Commercial Act amendment (mandatory treasury-share cancellation) [S63]Directly affects the 27.7% treasury stake
25 Feb 2026Microneedle obesity platform licence (Daewoong Therapeutics) [S32]Obesity entry
3 Mar 2026Evolus FY2025: USD 297.2 m revenue; FY2026 guidance USD 327–337 m [S66]Partner demand visibility
6 Mar 2026Amended Commercial Act takes effect; CG Bio: IMM PE preferred bidder [S64][S33]Cancellation clock starts (to 5 Sep 2027)
26 Mar 2026Daewoong Pharmaceutical AGM (co-CEO Park re-election, new outside directors); standing auditor retires [S92][S96]Management continuity
2 Apr 2026Batoclimab misses primary endpoints in both TED Phase 3 trials [S31]Negative for HanAll and for group NAV
Apr 2026White House announces a 15% tariff on patented pharmaceuticals from Korea (applies to Jeuveau from 29 Sep 2026 absent an exception) [S86]Margin and volume risk for Nabota in the US
17 Apr 2026Fexuprazan approved in Indonesia; approvals in 16 of 30 contracted countries [S68]Global footprint
12 May 2026Q1 2026: consolidated OP KRW 22.2 bn (−42.6%) on ETC channel reset; guidance maintained [S80]Temporary earnings dip
13 May 2026INV-008 IBD licence-in (KRW 662.5 bn) [S99]Pipeline expansion
18 Jun 2026IMM PE expected to sign for 51% of CG Bio at KRW 561.0 bn [S105]Owner-level liquidity event
2–8 Jul 2026IMM PE talks suspended; TA Associates named preferred bidder [S106][S116]Deal uncertainty
13 Jul 2026Nabota cumulative sales exceed KRW 1 tn [S23][S24]Franchise milestone; 2030 target restated
29 Jul 2026Q2 2026: record consolidated revenue KRW 448.5 bn, OP KRW 68.1 bn; Nabota exports +54.2% (tariff pull-forward) [S13][S16]Beat, with timing benefit
Aug 2026H1 report: cumulative Medytox litigation provision KRW 57.96 bn [S56b]Accounting reserve far below the claim
31 Aug–2 Sep 2026Medytox raises its appeal claim to KRW 500.1 bn (incl. KRW 1 bn against Daewoong Co.) [S117][S118]Material tail risk (about 44% of Daewoong Pharmaceutical's equity per Biobook)
6 Sep 2026ERS 2026: bersiporocin baseline data; topline H1 2027 [S111]Key 2027 catalyst set
Sep 2026Fexuclue gastric-ulcer Phase 3 IND approved (disclosed by Daewoong Co.) [S39]Lifecycle extension
17 Sep 2026Closed appeal hearing at Seoul High Court [S56]Litigation progress
2 Oct 2026Daewoong Co. closes at KRW 15,340, near its 52-week low (KRW 15,040) [S37]Roughly half its February 2026 peak
8 Oct 2026Seoul High Court closes arguments; judgment expected January 2027 [S57]Binary catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

7 charts
Revenue by Segment: Daewoong Co. consolidated revenue to OTC (incl. health-functional foods from 2025 presentation): Daewoong Co. consolidated revenue rose from KRW 1,813.8 Bn in FY2023 to KRW 2,068.6 Bn in FY2025.
Daewoong Co., Ltd. — Revenue by Segment: Daewoong Co. consolidated revenue to OTC (incl. health-functional foods from 2025 presentation)
Series (KRW Bn)FY2023FY2024FY2025
Daewoong Co. consolidated revenue1,813.81,936.92,068.6
Daewoong Pharmaceutical consolidated revenue1,375.31,422.71,570.9
Daewoong Bio revenue511.7579.7641.3
HanAll Biopharma revenue (inside Daewoong Pharmaceutical)134.9138.9155.2
ETC (prescription)872.5860.5894.2
OTC (incl. health-functional foods from 2025 presentation)115.2133.3162.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. S1Stockopedia — Daewoong Co Ltd profile (subsidiary list) (stockopedia.com)
  2. S2Google Finance — 003090:KRX (quarterly income data, employees, founding date) (google.com)
  3. S3StockAnalysis — Daewoong Co. (KRX:003090) profile and Arcera partnership headline (stockanalysis.com)
  4. S4Multiples.vc — Daewoong valuation multiples (multiples.vc)
  5. S5aPaasa — Daewoong statements FY2021–FY2025 (paasa.com)
  6. S5bInvesting.com UK — Daewoong ratios (uk.investing.com)
  7. S5cStoxray — 003090 history (stoxray.com)
  8. S6Investing.com — Daewoong (003090) (investing.com)
  9. S6bStockHub — Daewoong English page (NPS holding) (stockhub.kr)
  10. S7Morningstar Australia — Daewoong Co Ltd summary (morningstar.com.au)
  11. S8Medigatenews — 63rd AGM (FY2022) (medigatenews.com)
  12. S9Medigatenews — 65th AGM, dividend raised to KRW 200 (FY2024) (medigatenews.com)
  13. S10Nate/News — Daewoong Pharmaceutical FY2025 OP and Daewoong Co. FY2025 group figures (m.news.nate.com)
  14. S11KRX KIND — Daewoong Pharmaceutical FY2025 business report (24th) (kind.krx.co.kr)
  15. S11bDealsite — Daewoong Pharmaceutical FY2025 results by division (dealsite.co.kr)
  16. S12Dealsite — Daewoong Pharmaceutical FY2024 results (dealsite.co.kr)
  17. S13Kormedi — Q2 2026 results (kormedi.com)
  18. S14MTN — Q2 2026, tariff pull-forward, thynC (news.mtn.co.kr)
  19. S16Herald Corp — Q2 2026 record quarter (mbiz.heraldcorp.com)
  20. S17Dealsite — Q3 2025 results (dealsite.co.kr)
  21. S18Kiwoom Securities — Q1 2026 review (product sales) (bbn.kiwoom.com)
  22. S19TheVC — Daewoong (thevc.kr)
  23. S19bCatch — Daewoong company summary (separate revenue) (m.catch.co.kr)
  24. S20Hankyung Magazine — 64th AGM (FY2023) (magazine.hankyung.com)
  25. S20bDealsite — CEO change, Mar 2024 (dealsite.co.kr)
  26. S21Bizwatch — 63rd AGM (news.bizwatch.co.kr)
  27. S22iNews24 — 62nd AGM (FY2021) (inews24.com)
  28. S22bDailypharm — 61st AGM (FY2020) (m.dailypharm.com)
  29. S23Asia Economy — Nabota KRW 1 tn cumulative (view.asiae.co.kr)
  30. S24Medigatenews — Nabota KRW 1 tn, 16 m vials, 2030 target (medigatenews.com)
  31. S24bKukinews — Nabota KRW 1 tn, MFDS export record (kukinews.com)
  32. S27KRX KIND — Daewoong Pharmaceutical report (parent and subsidiaries), Aug 2025 (kind.krx.co.kr)
  33. S28DigitalToday — Daewoong Pharmaceutical major-shareholder filing, Mar 2026 (digitaltoday.co.kr)
  34. S29Dailypharm — Daewoong Bio FY2025 (dailypharm.com)
  35. S30Biospectator — HanAll FY2025 and pipeline (biospectator.com)
  36. S31BioSpace — Immunovant batoclimab TED Phase 3 results (biospace.com)
  37. S32Korea Herald — Microneedle licence (koreaherald.com)
  38. S33Dealsite — CG Bio sale to IMM PE begins (dealsite.co.kr)
  39. S34HuffPost Korea — Yoon Jae-seung, CG Bio, holdings (huffingtonpost.kr)
  40. S36Investing.com — Daewoong (Aug 2026 data) (investing.com)
  41. S37MSN Money — Daewoong 003090 (2 Oct 2026) (msn.com)
  42. S38Chickstock — 003090 (Sep 2026; Q1 2026 revenue) (chickstockfi.com)
  43. S39StockHub — 003090 (treasury 27.70%; Fexuclue IND disclosure) (stockhub.kr)
  44. S40KRX KIND — Daewoong Co. Q3 2025 quarterly report (kind.krx.co.kr)
  45. S41Kukinews via Daum — treasury-share swaps (v.daum.net)
  46. S42Dealsite — U2Bio share swap (dealsite.co.kr)
  47. S43GoInsider — Daewoong disclosures and holders (goinsider.kr)
  48. S44Kormedi — 2017 AGM, stock split (kormedi.com)
  49. S45Nate/DigitalToday — FY2025 dividend decision (m.news.nate.com)
  50. S46Kormedi — founder obituary and history (kormedi.com)
  51. S47Dailypharm — 1945 "liberation-era" companies history (dailypharm.com)
  52. S48HappyCampus — Daewoong history summary (secondary) (happycampus.com)
  53. S49Kormedi — three 2023 licensing deals (kormedi.com)
  54. S50Dailypharm — HanAll acquisition 2015 and group synergies (dailypharm.com)
  55. S51Medical Times — Nabota plant 2 KGMP (2017) (medicaltimes.com)
  56. S52Newstomato — Daewoong Pharmaceutical audit and revenue history (newstomato.com)
  57. S53Nate/iNews24 — Medytox claim and US settlement background (m.news.nate.com)
  58. S54iNews24 — Fexuclue approval (2021) (inews24.com)
  59. S55Daum/MK — Fexuclue and Envlo background (v.daum.net)
  60. S56Weekly Hankook — Medytox appeal, stay deposits (weekly.hankooki.com)
  61. S56bIssue Valley — H1 2026 litigation provision; R&D ratio (issuevalley.com)
  62. S57Edaily — appeal arguments closed; judgment January (edaily.co.kr)
  63. S57bSeoul Ilbo — capex (Nabota plant, Magok) (seoulilbo.co.kr)
  64. S58MarketScreener — Neurogastrx termination (marketscreener.com)
  65. S59Korea Biomedical Review — Fexuclue India with Sun Pharma (koreabiomed.com)
  66. S60Bosa (Medical Daily) — 65 listed pharma FY2025 (bosa.co.kr)
  67. S61Dailypharm — KCGS 2025 ratings (dailypharm.com)
  68. S62Dealsite — Daewoong Pharmaceutical first KCGS A (dealsite.co.kr)
  69. S62bDailypharm — ESG grade trajectory (dailypharm.com)
  70. S63Taxtimes — Commercial Act amendment passage (taxtimes.co.kr)
  71. S64CEO& — amended Commercial Act effective 6 Mar 2026 (ceopartners.co.kr)
  72. S65SK Securities — Daewoong Pharmaceutical Q4 2024 and divisions (file.alphasquare.co.kr)
  73. S66MarketBeat — Evolus Q4 2025 call highlights (marketbeat.com)
  74. S67Kormedi — Nabota KRW 1 tn and aesthetics roadmap (kormedi.com)
  75. S68Daewoong Pharmaceutical Indonesia — fexuprazan approval (Apr 2026) (daewoongpharm.id)
  76. S69Dailypharm — Q1 2025; Envlo 19 countries (m.dailypharm.com)
  77. S70Newsspace — outpatient prescriptions above KRW 1 tn (newsspace.kr)
  78. S71Kormedi — 2018 in-licensed products (historical) (kormedi.com)
  79. S72HappyCampus — product brand list (secondary) (happycampus.com)
  80. S73Dealsite — thynC installations (dealsite.co.kr)
  81. S74Dailypharm — Daewoong Bio Gliatamin (2024) (m.dailypharm.com)
  82. S75Dailypharm — Daewoong Bio H1 2025 (dailypharm.com)
  83. S76Ophthalmology Times — batoclimab TED (ophthalmologytimes.com)
  84. S77Dailypharm English — HanAll/Immunovant timelines (dailypharm.com)
  85. S78Mirae Asset — Daewoong (May 2024; Fexuclue impairment note) (securities.miraeasset.com)
  86. S79OpenBizData — Daewoong Pharmaceutical FY2025 analysis (openbizdata.com)
  87. S80Kyobo Securities — Q1 2026 review and guidance (stock.pstatic.net)
  88. S81StockHub/Kiwoom — Q2 2026 beat summary (stockhub.kr)
  89. S81bBroker brief (Naver research) — Q2 2026 company brief (stock.pstatic.net)
  90. S82Valueline Korea — Daewoong consolidated balance sheet and prices (valueline.co.kr)
  91. S83Samsung Securities — Daewoong Pharmaceutical (Nov 2025) (samsungpop.com)
  92. S84FnGuide — Daewoong separate financial highlights (comp.fnguide.com)
  93. S85Wisesheets — 003090 current ratio (wisesheets.io)
  94. S86SEC EDGAR — Evolus Q1 2026 8-K exhibit (tariff and guidance) (sec.gov)
  95. S87Korea Biomedical Review — EMS Fexuclue termination (koreabiomed.com)
  96. S88Medifonews — Daewoong Pharmaceutical 23rd AGM (medifonews.com)
  97. S89JobPlanet — Daewoong Pharmaceutical company profile (jobplanet.co.kr)
  98. S90Kormedi — Osong plant depreciation (2018) (kormedi.com)
  99. S91Medical Times — Osong and Hyangnam cGMP investment (medicaltimes.com)
  100. S92Sidae — Park Seong-soo re-election outlook (Mar 2026) (sidae.com)
  101. S93Kormedi — 62nd AGM stock-dividend proposal rejected (kormedi.com)
  102. S94CEO Score Daily — 23rd AGM (ceoscoredaily.com)
  103. S95Newstomato — auditor expertise critique (newstomato.com)
  104. S96DigitalToday — auditor retirement (Mar 2026) (digitaltoday.co.kr)
  105. S97HuffPost Korea — treasury-share ratio history (huffingtonpost.kr)
  106. S98Korea Biomedical Review — microneedle obesity licence (koreabiomed.com)
  107. S99Seoul Economic Daily — INV-008 licence-in (en.sedaily.com)
  108. S100Dailypharm — group capital recycling (m.dailypharm.com)
  109. S101Littlebit — U2Bio limit-up on Daewoong investment (mydailybyte.com)
  110. S102BioSpace — Neurogastrx 2021 licence (biospace.com)
  111. S102bWeekly Hankook — security-note disclosure issue (weekly.hankooki.com)
  112. S103Kormedi — Zydus leuprolide depot deal (kormedi.com)
  113. S104Dailypharm — CG Bio sale imminent (dailypharm.com)
  114. S105Hankyung — IMM PE CG Bio terms (hankyung.com)
  115. S106Dailypharm — preferred bidder changed to TA Associates (m.dailypharm.com)
  116. S107Kormedi — TA Associates negotiation (kormedi.com)
  117. S108Medical Times — CG Bio deal deadline (Aug 2026) (medicaltimes.com)
  118. S109The Fact — CG Bio sale and owner control (news.tf.co.kr)
  119. S110MTN — Chong Kun Dang in-licensing margins (news.mtn.co.kr)
  120. S111Kyodo/PR Newswire — bersiporocin ERS 2026 (kyodonewsprwire.jp)
  121. S112Korea Herald/PR Newswire — third IDMC (koreaherald.com)
  122. S113Dailypharm — Envlo triple-combination Phase 3 (headline) (dailypharm.com)
  123. S114Dailypharm — Q1 2025 results (m.dailypharm.com)
  124. S115SK Securities — Q2 2025 review (file.alphasquare.co.kr)
  125. S116Daum/Chosun Biz — IMM non-compete dispute (v.daum.net)
  126. S117Kyungje Ilbo — Medytox claim KRW 500 bn (kyungjeilbo.com)
  127. S118Biobook — KRW 500.1 bn claim (44% of equity) (biobookmedia.com)
  128. S119Bizwatch — pharma league table FY2025 (news.bizwatch.co.kr)
  129. S120HuffPost Korea — FY2025 pharma results (huffingtonpost.kr)
  130. S121Medifonews — TOP50 pharma; Hanmi Science (medifonews.com)
  131. S122Dealsite — Hugel FY2025 (dealsite.co.kr)
  132. S123Medical Times — Hugel vs Medytox FY2025 (medicaltimes.com)
  133. S124Yahoo Finance — Evolus Q4 2025 call summary (finance.yahoo.com)
  134. S125Money Today — Daewoong Pharmaceutical price (22 Sep 2026) (mt.co.kr)
  135. S125bStockHub — Daewoong Pharmaceutical consensus (stockhub.kr)
  136. S126Newstomato — toxin national core technology debate (newstomato.com)
  137. S127KRX KIND — Q1 2026 quarterly report extract (kind.krx.co.kr)
  138. S128Dailypharm — ESG ratings by agency (dailypharm.com)
  139. S129Newstomato — 2nd/3rd-generation owner scorecards (newstomato.com)
  140. S130Joongang Economy News — Daewoong +16.6% (Jul 2025) (joongangenews.com)
  141. S131Littlebit — after-market +10.23% to KRW 30,700 (mydailybyte.com)
  142. S132Nate/MT — treasury-share policy undecided (Mar 2026) (m.news.nate.com)
  143. S133Kiwoom Securities — Q4 2025 review (bbn.kiwoom.com)
  144. S134KPA News — H1 2026 results of KRW 1 tn-revenue pharma companies (kpanews.co.kr)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.